Divi's Laboratories Ltd.'s third-quarter profit increased, beating estimates.
Consolidated net profit for the company rose 64.5% year-on-year to Rs 589 crore in the three months through Dec. 31, 2024, according to its exchange filing on Monday. That compares with the Rs 500-crore consensus estimate of analysts tracked by Bloomberg.
Divi's Laboratories Q3 Highlights (Consolidated, YoY)
Revenue up 25% at Rs 2,319 crore versus Rs 1,855 crore (Bloomberg estimate: Rs 2,255 crore).
Ebitda up 52% at Rs 743 crore versus Rs 489 crore (Estimate: Rs 690 crore).
Ebitda margin at 32% versus 26.4% (Estimate: 30.6%).
Net profit up 64.5% at Rs 589 crore versus Rs 358 crore (Estimate: Rs 500 crore).
The board approved the re-appointment of Dr. Kiran Divi as whole-time director and chief executive officer for five years with effect from April 1, 2025, subject to shareholders' approval.
Shares of Divi's Labs were trading 2% higher at Rs 5,735 apiece on the NSE, compared to 0.6% fall in the benchmark Nifty 50.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
